Publications by authors named "Ignacio Matos"

Claim this Profile
F
Fcγ receptors and immunomodulatory antibodies in cancer.
Felipe Galvez-Cancino, Alexander P Simpson, Cristobal Costoya, Ignacio Matos, Danwen Qian

Nat Rev Cancer· January 2024

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
S
Survival and safety after neoadjuvant chemotherapy or upfront surgery for locally advanced colon cancer: meta-analysis.
Daniel Aliseda, Jorge Arredondo, Carlos Sánchez-Justicia, Alicia Alvarellos, Javier Rodríguez, Ignacio Matos

Br J Surg· January 2024

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
D
Druggable Targets in Cytokine Release Syndromes.
Carlos Luri-Rey, Iñaki Eguren-Santamaria, Ignacio Matos, Pedro Berraondo, Ignacio Melero

Clin Cancer Res· November 2023

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
E
Exploring the Immunogenicity of Noncanonical HLA-I Tumor Ligands Identified through Proteogenomics.
Maria Lozano-Rabella, Andrea Garcia-Garijo, Jara Palomero, Anna Yuste-Estevanez, Florian Erhard, Ignacio Matos

Clin Cancer Res· June 2023

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
L
Low Risk of Hyperprogression with First-Line Chemoimmunotherapy for Advanced Non-Small Cell Lung Cancer: Pooled Analysis of 7 Clinical Trials.
Lee X Li, Federico Cappuzzo, Ignacio Matos, Mark A Socinski, Ashley M Hopkins

Oncologist· April 2023

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
A
Anti-CTLA-4 antibodies drive myeloid activation and reprogram the tumor microenvironment through FcγR engagement and type I interferon signaling.
Ido Yofe, Tomer Landsberger, Adam Yalin, Isabelle Solomon, Cristobal Costoya, Ignacio Matos

Nat Cancer· November 2022

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
A
Author Correction: Anti-CTLA-4 antibodies drive myeloid activation and reprogram the tumor microenvironment through FcγR engagement and type I interferon signaling.
Ido Yofe, Tomer Landsberger, Adam Yalin, Isabelle Solomon, Cristobal Costoya, Ignacio Matos

Nat Cancer· November 2022

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
P
Phase I prognostic online (PIPO): A web tool to improve patient selection for oncology early phase clinical trials.
Ignacio Matos, Guillermo Villacampa, Cinta Hierro, Juan Martin-Liberal, Roger Berché

Eur J Cancer· September 2021

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
P
Pralsetinib for patients with advanced or metastatic RET-altered thyroid cancer (ARROW): a multi-cohort, open-label, registrational, phase 1/2 study.
Vivek Subbiah, Mimi I Hu, Lori J Wirth, Martin Schuler, Aaron S Mansfield, Ignacio Matos

Lancet Diabetes Endocrinol· August 2021

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
L
Lenvatinib in Patients With Advanced Grade 1/2 Pancreatic and Gastrointestinal Neuroendocrine Tumors: Results of the Phase II TALENT Trial (GETNE1509).
Jaume Capdevila, Nicola Fazio, Carlos Lopez, Alexandre Teulé, Juan W Valle, Ignacio Matos

J Clin Oncol· July 2021

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
E
Efficacy and safety of pembrolizumab in patients with advanced mesothelioma in the open-label, single-arm, phase 2 KEYNOTE-158 study.
Timothy A Yap, Kazuhiko Nakagawa, Nobukazu Fujimoto, Kozo Kuribayashi, Tormod Kyrre Guren, Ignacio Matos

Lancet Respir Med· June 2021

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
A
A CT-based Radiomics Signature Is Associated with Response to Immune Checkpoint Inhibitors in Advanced Solid Tumors.
Marta Ligero, Alonso Garcia-Ruiz, Cristina Viaplana, Guillermo Villacampa, Maria V Raciti, Ignacio Matos

Radiology· April 2021

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
C
Clarification of Definitions of Hyperprogressive Disease During Immunotherapy.
Ignacio Matos, Elena Garralda

JAMA Oncol· January 2021

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
T
The PALBONET Trial: A Phase II Study of Palbociclib in Metastatic Grade 1 and 2 Pancreatic Neuroendocrine Tumors (GETNE-1407).
Enrique Grande, Alex Teulé, Teresa Alonso-Gordoa, Paula Jiménez-Fonseca, Marta Benavent, Ignacio Matos

Oncologist· September 2020

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
A
Atypical patterns of response and progression in the era of immunotherapy combinations.
Roberto Ferrara, Ignacio Matos

Future Oncol· August 2020

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
C
Capturing Hyperprogressive Disease with Immune-Checkpoint Inhibitors Using RECIST 1.1 Criteria.
Ignacio Matos, Juan Martin-Liberal, Alonso García-Ruiz, Cinta Hierro, Maria Ochoa de Olza

Clin Cancer Res· April 2020

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
P
Pembrolizumab After Two or More Lines of Previous Therapy in Patients With Recurrent or Metastatic SCLC: Results From the KEYNOTE-028 and KEYNOTE-158 Studies.
Hyun Cheol Chung, Sarina A Piha-Paul, Jose Lopez-Martin, Jan H M Schellens, Steven Kao, Ignacio Matos

J Thorac Oncol· April 2020

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
H
Hyperprogression and Immunotherapy: Fact, Fiction, or Alternative Fact?
Jacob J Adashek, Ishwaria M Subbiah, Ignacio Matos, Elena Garralda, Arjun K Menta

Trends Cancer· March 2020

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
E
Epigenetic Gene Repression Confers Sensitivity to Therapeutic BRAFV600E Blockade in Colon Neuroendocrine Carcinomas.
Jaume Capdevila, Oriol Arqués, Jose Ramón Hernández Mora, Judit Matito, Ginevra Caratù, Ignacio Matos

Clin Cancer Res· February 2020

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
I
Identification of Expression Profiles Defining Distinct Prognostic Subsets of Radioactive-Iodine Refractory Differentiated Thyroid Cancer from the DECISION Trial.
Jaume Capdevila, Ignacio Matos, Francesco M Mancuso, Carmela Iglesias, Paolo Nuciforo

Mol Cancer Ther· January 2020

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
E
Evaluating radiological response in pancreatic neuroendocrine tumours treated with sunitinib: comparison of Choi versus RECIST criteria (CRIPNET_ GETNE1504 study).
Mª Pilar Solis-Hernandez, Ana Fernandez Del Valle, Alberto Carmona-Bayonas, Rocio Garcia-Carbonero, Ana Custodio, Ignacio Matos

Br J Cancer· October 2019

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
A
Agnostic-Histology Approval of New Drugs in Oncology: Are We Already There?
Cinta Hierro, Ignacio Matos, Juan Martin-Liberal, Maria Ochoa de Olza, Elena Garralda

Clin Cancer Res· June 2019

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
T
Triple-drug chemotherapy regimens in combination with an anti-EGFR agent in metastatic colorectal cancer - prospects from phase II clinical trials.
Ignacio Matos, Alba Noguerido, Javier Ros, Nuria Mulet, Guillem Argilés

Expert Opin Investig Drugs· May 2019

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
P
Phase II Study of Everolimus and Octreotide LAR in Patients with Nonfunctioning Gastrointestinal Neuroendocrine Tumors: The GETNE1003_EVERLAR Study.
Jaume Capdevila, Alexandre Teulé, Jorge Barriuso, Daniel Castellano, Carlos Lopez, Ignacio Matos

Oncologist· January 2019

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
T
The safety of ramucirumab for the treatment of colorectal cancer.
Alba Noguerido, Núria Mulet-Margalef, Ignacio Matos, Javier Ros, Guillem Argilés

Expert Opin Drug Saf· September 2018

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis